A recent BMJ study highlights psilocybin’s potential as an effective antidepressant, demonstrating substantial improvement in depression symptoms compared to traditional controls. Researchers stress the need for more detailed studies to understand its therapeutic potential fully.
Psilocybin has shown promise in reducing symptoms of depression after one or two doses with few side effects and no current evidence of causing addiction. However, studies published to date have not investigated factors that may moderate psilocybin’s effects, including type of depression, past use of psychedelics, dosage, and publication biases.
The change in depression scores was significantly greater after treatment with psilocybin than with a comparator treatment, with an overall Hedge’s g of 1.64 indicating a large effect size favoring psilocybin. Furthermore, in clinical trials, patients receive psilocybin in a calm living room with soothing music, supervised by a psychotherapist, which is unlikely to be achievable in a healthcare system.
For instance, they argue that it cannot provide evidence for psilocybin’s effectiveness in depression until more information about potential effect modifiers is gathered, and that pragmatic clinical trials and real world data could help to deliver that.
Technology Technology Latest News, Technology Technology Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: futurism - 🏆 85. / 68 Read more »